Skip to content
Screener
Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

VRTX

Vertex Pharmaceuticals is a global biotechnology company dedicated to developing transformative medicines for serious diseases with a focus on specialty markets.

Market cap
$138.72B+39.1%
Revenue$12.6B+10.2%
Net income$4.4B+607%
EPS (diluted)$17.17+601%
Trailing twelve months · change vs. prior year

Earnings

Next report

Nov 2, 2026 (in 2 months)
Revenue estimate$3.4B
EPS estimate$4.80

Financials

Q2 2026

Income statement

See full
Revenue$3.3B+12.5%
Gross profit$2.8B+11.2%
Operating income$1.2B+8.3%
Net income$1.1B+6.5%
EPS (diluted)$4.31+8.0%

Balance sheet

See full
Cash & equivalents$7.9B+57.6%
Total debt$2.0B+29.5%
Total equity$20.2B+17.9%
Total assets$27.4B+14.1%

Valuation & ratios

Valuation

See full
Market cap$138.72B+39.1%
Enterprise value$132.84B+37.9%
P/E31.5×
P/S11×+2.3×

Profitability

See full
Gross margin86%-0.1pp
Operating margin38%
Net margin35%

Returns & leverage

See full
Return on equity23.5%
Debt / equity0.1×0.0×
Current ratio3.2×+0.7×

Segments

By product

See full
TRIKAFTA/KAFTRIO$2.5B-2.1%
ALYFTREK$573.6M+266%
CASGEVY$76.4M
JOURNAVX$49.6M

Competitors

Profile

Vertex Pharmaceuticals is a global biotechnology company dedicated to developing transformative medicines for serious diseases with a focus on specialty markets. The company leverages a serial innovation strategy to discover and commercialize therapies that address the underlying causes of diseases such as cystic fibrosis, sickle cell disease, and acute pain. Their approach combines deep human biology insights with advanced therapeutic modalities to deliver first-in-class and best-in-class treatments.

Competitive position

Vertex is the dominant leader in the cystic fibrosis market and a pioneer in CRISPR-based gene editing and non-opioid pain treatments.

GeographiesUnited States, Europe, Australia, Canada
Customer segmentsPatients with rare diseases, Specialized healthcare systems, Government health programs
Business modelR&D-driven drug development, Specialty pharmaceutical commercialization
SuppliersSpecialized raw material suppliers, Contract manufacturing organizations, Academic research institutions, Genetic sequencing providers
CustomersSpecialty drug distributors, Public and private insurers, Specialized medical centers
Listed1991
Employees5.4K
CEOReshma Kewalramani
Websitevrtx.com
FilingsSEC EDGAR

FAQ

What is Vertex Pharmaceuticals's market cap?
Vertex Pharmaceuticals (VRTX) has a market capitalization of $138.72B and trades on NASDAQ.
What is Vertex Pharmaceuticals's revenue and profitability?
Vertex Pharmaceuticals generated $12.6B in trailing twelve-month revenue with net income of $4.4B, representing a net margin of 35.0%. Gross margin stands at 86.0%. These figures are based on the Q2 2026 filing.
Who are Vertex Pharmaceuticals's competitors?
Vertex Pharmaceuticals's key competitors include AbbVie, Fulcrum Therapeutics, Inc. Common Stock, Sionna Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Vertex Pharmaceuticals partner with?
Vertex Pharmaceuticals's notable partners include CRISPR Therapeutics.
What subsidiaries does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals's subsidiaries include Alpine Immune Sciences.
Where is Vertex Pharmaceuticals headquartered?
Vertex Pharmaceuticals is headquartered in United States of America and employs approximately 5,400 people. It has been publicly traded since 1991.